Nektar Therapeutics (NKTR)
83.22
+1.96
(+2.41%)
USD |
NASDAQ |
Apr 15, 16:00
83.01
-0.21
(-0.25%)
After-Hours: 20:00
Nektar Therapeutics Research and Development Expense (Annual) : 117.07M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Boston Scientific Corp. | 2.052B |
| Soleno Therapeutics, Inc. | 40.63M |
| Eli Lilly & Co. | 13.34B |
| Regeneron Pharmaceuticals, Inc. | 5.306B |
| Esperion Therapeutics, Inc. | 47.85M |